On October 16, 2019 Enzychem Lifesciences, a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, reported that three abstracts have been accepted for poster presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), on October 26-30, 2019, at the Hynes Convention Center in Boston, Massachusetts (Press release, Enzychem Lifesciences, OCT 16, 2019, View Source [SID1234542321]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new data demonstrates Enzychem Lifesciences’ commitment to fully understanding of EC-18’s mechanism of action on transendothelial migration & tissue infiltration of neutrophils, as well as potential antitumor effects of EC-18 in the therapeutic indications.

"Tumor infiltrating neutrophils play an important role in tumor progression and metastasis. There is a great need for developing a drug such as EC-18 that may reduce tumor metastasis through novel mechanism of modulating neutrophil trafficking," said Dr. Jeff Crawford, Chairperson of scientific advisory board of Enzychem Lifesciences.

Poster presentation details:

Title: A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia

Abstract: A070

Date/Time: Sunday Oct 27, 12:30pm – 4:00 pm

Location: Board 70

Title: The synergistic effect of PLAG on the antitumor efficacy of AC-regimen via alleviating neutrophil tumor infiltration on breast tumor xenograft model

Abstract Number: B054

Date/Time: Monday Oct 28, 12:30pm – 4:00pm

Location: Board 54

Title: Anti-metastatic effect of PLAG via interference of neutrophil elastase/PAR2/EGFR signaling on A549 lung cancer orthotopic implantation model

Abstract Number: C037

Date/Time: Tuesday Oct 29, 12:30pm – 4:00 pm

Location: Board 37